PAR 1.64% 31.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-4279

  1. 559 Posts.
    lightbulb Created with Sketch. 232



    Pradobefree, the last we were told is that the 2b peer review, would be combined with the 008 review and released together.
    I see from the deck used in WA last week, that the 008 peer review was labelled on its own in the upcoming catalyst section. Maybe that is a mistake or they labelled it that way for another reason, but we have been promised a 2b review for at least 4 years now and from their latest printed materials, it looks like we won't be getting one.

    I do recall from 2 AGMs ago, the CEO who cried wolf, go off on a tangent and tell us that a 2b peer review didn't matter, because the FDA had granted him P3 status.... Just another misdirection, we can log into the journal.

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
31.0¢
Change
0.005(1.64%)
Mkt cap ! $108.4M
Open High Low Value Volume
31.5¢ 31.5¢ 29.5¢ $98.05K 323.7K

Buyers (Bids)

No. Vol. Price($)
1 29159 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
31.0¢ 4999 1
View Market Depth
Last trade - 16.10pm 18/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.